scholarly journals Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

2020 ◽  
Vol 3 (10) ◽  
pp. e2016144
Author(s):  
Tina R. Watson ◽  
Xin Gao ◽  
Kerry L. Reynolds ◽  
Chung Yin Kong
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
The Us ◽  
First Line Treatment

scholarly journals Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

2020 ◽  
Vol 36 (9) ◽  
pp. 1507-1517
Author(s):  
Arielle G. Bensimon ◽  
Yichen Zhong ◽  
Umang Swami ◽  
Allison Briggs ◽  
Joshua Young ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

2010 ◽  
Vol 13 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Martin Hoyle ◽  
Colin Green ◽  
Jo Thompson-Coon ◽  
Zulian Liu ◽  
Karen Welch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document